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Identifying a gene expression 
signature of cluster headache  
in blood
Else Eising1, Nadine Pelzer2, Lisanne S. Vijfhuizen1, Boukje de Vries1, Michel D. Ferrari2, 
Peter A. C. ‘t Hoen1, Gisela M. Terwindt2 & Arn M. J. M. van den Maagdenberg1,2
Cluster headache is a relatively rare headache disorder, typically characterized by multiple daily, short-
lasting attacks of excruciating, unilateral (peri-)orbital or temporal pain associated with autonomic 
symptoms and restlessness. To better understand the pathophysiology of cluster headache, we used 
RNA sequencing to identify differentially expressed genes and pathways in whole blood of patients 
with episodic (n = 19) or chronic (n = 20) cluster headache in comparison with headache-free controls 
(n = 20). Gene expression data were analysed by gene and by module of co-expressed genes with 
particular attention to previously implicated disease pathways including hypocretin dysregulation. Only 
moderate gene expression differences were identified and no associations were found with previously 
reported pathogenic mechanisms. At the level of functional gene sets, associations were observed 
for genes involved in several brain-related mechanisms such as GABA receptor function and voltage-
gated channels. In addition, genes and modules of co-expressed genes showed a role for intracellular 
signalling cascades, mitochondria and inflammation. Although larger study samples may be required to 
identify the full range of involved pathways, these results indicate a role for mitochondria, intracellular 
signalling and inflammation in cluster headache.
Cluster headache is a relatively rare brain disorder, typically characterized by multiple-daily, short-lasting 
(15–180 min) attacks of excruciating, unilateral, (peri-)orbital or temporal headache associated with ipsilateral 
facial autonomic symptoms and restlessness1,2. In up to 90% of patients, attacks strike in defined periods of several 
weeks to months alternating with attack-free periods of several months to years (episodic cluster headache). In 
the remaining 10%, attacks keep on recurring without attack-free periods longer than a month (chronic cluster 
headache). The lifetime prevalence is 0.05–0.4%3,4 and the male-to-female ratio 4.4: 14,5.
The etiology of cluster headache is unknown. Triggered by neuroimaging data and the circadian and annual 
rhythmicity of attacks and periods of cluster headache, an important role has been postulated for the hypo-
thalamus and the sleep-, pain-, and autonomic function-modulating, hypothalamic neuropeptide hypocretin 
(orexin)6–9. Activation of the trigeminovascular system and possibly associated inflammatory processes have been 
implicated in causing and aggravating the pain10–12. Although family members of cluster headache patients seem 
to be at increased risk of developing cluster headache3, indicating contribution of genetic factors, genetic studies 
into cluster headache have been largely unsuccessful13,14. Some studies suggested involvement of the HCRTR2 
gene that encodes the hypocretin type 2 receptor, but this finding could not be confirmed in other studies15. A 
main complicating factor for genetic association studies in cluster headache is that they included at best only a few 
hundred cases rather than the many thousands which are usually required for such studies.
Gene expression profiling is an alternative approach to identify disease genes and pathways requiring only 
several tens of cases. However, as well-characterized human post-mortem brain samples are difficult to obtain 
in these numbers, gene expression profiling studies for brain disorders have been mostly performed in whole 
blood samples. Promising results were obtained for epilepsy16 and psychiatric17,18 and neurodegenerative dis-
orders19–23, with gene expression differences similar to those observed in post-mortem brain material19–23. Two 
gene expression profiling studies using microarray technology have been performed in cluster headache24,25. In 
one, whole blood gene expression levels from three cluster headache patients and three controls were compared; 
90 differentially expressed genes were identified, including upregulated calcium-binding proteins suggesting 
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a possible role for non-infectious inflammation25. In the other study, immortalized lymphoblastoid cell lines 
from eight lithium-responsive cluster headache patients and 10 controls were compared26. Over 1,100 differ-
entially expressed genes were identified of which many are involved in endoplasmic reticulum protein process-
ing25. Remarkably, only 10 genes overlapped between both studies, of which six showed differential expression 
when comparing the same patient outside and during a cluster period in-between attacks24. The limited overlap 
between these studies is likely explained by the small sample sizes and differences in gender, age, medication, 
tissues, and other factors.
RNA-sequencing (RNA-seq) is a deep sequencing-based technique that is more robust and detects a wider 
range of transcripts than microarray technology26. In the present study, we used RNA-seq to compare whole blood 
gene expression profiles of 39 well characterized participants with cluster headache (19 episodic; 20 chronic) and 
20 matched controls. Besides analysing the RNA-seq data per gene, a clustering approach was applied to group 
genes into modules based on co-expression and study the association of these modules with cluster headache. 
Special attention was given to hypocretin-related genes and genes previously found to be differentially expressed 
in cluster headache.
Results
Whole blood gene expression profiles of 40 participants with cluster headache (20 episodic; 20 chronic) and 20 
controls were obtained using an RNA-seq approach. The RNA-seq data of one participant with episodic cluster 
headache were excluded because of inferior RNA-seq data quality (Table 1). In participants with cluster head-
ache, blood samples were collected outside attacks; in 25/39 participants within one day from the last attack 
(10 episodic and 15 chronic patients), in 8/39 participants between one to seven days (4 episodic and 4 chronic 
patients), and in the remaining 6 within 94 days (5 episodic and 1 chronic patient). Participants with episodic 
cluster headache were studied within a “cluster period” (i.e. preventative treatment is still necessary because when 
lowering the treatment the patient perceives upcoming, or first symptomatology, of attacks). There were no dif-
ferences between participants with episodic and chronic cluster headache for attack frequency and medication 
use in the month prior to sampling. Leukocyte counts did not differ between participants with cluster headache 
and controls (Supplementary Table 1). On average 23.9 million high-quality paired-end sequencing reads were 
obtained per sample (range: 21.4–30.2 million). On average 91% (range: 88–93%) of reads could be uniquely 
aligned to the genome, of which 77% (range: 71–82%) to known exons. A total of 13,416 genes with sufficiently 
high expression (after removal of genes with< 1 count per million (CPM) in a minimum of 15 samples) were 
present in our dataset.
Identification of differentially expressed genes. Expression differences between participants with 
cluster headache and controls were very modest, in fact no gene was found significant with a False Discovery 
Rate (FDR) of 0.05 or 0.1 (Table 2). Removing samples (n = 2) with a large time (> 30 days) between inclusion 
and last attack did not affect results (Fig. S1). The Global Test, however, showed that the overall gene expression 
Controls Episodic CH Chronic CH P-value Controls vs CH
P-value Controls vs episodic vs 
chronic CH
Number of individuals 20 19 20
Age (years) 42.2 ± 12.4 40.0 ± 9.0 45.0 ± 13.4 0.97c 0.39c
Gender (M/F) 15/5 15/4 15/5 1d 0.86c
Current smokers (n) 10 10 11 0.79d 0.90d
Packyears (n) 11.6 ± 15.4 8.4 ± 11.5 14.7 ± 17.3 0.99c 0.49c
Days since latest attack — 6.8 ± 13.9 5.8 ± 20.8 — 0.70e
Attack frequency during 
month prior to sampling 
(#/day)
— 1.0 ± 1.3 1.9 ± 2.1 — 0.13e
Prophylactic treatment — —
- Verapamil 8 10 0.76f
- Othera 4 10 0.096f
- None 7 3 0.29f
Acute treatment — —
- Sumatriptan s.c. 13 15 0.73f
- Oxygen 6 11 0.22f
- Otherb 3 4 1f
- None 2 3 1f
Table 1. Demographics of the experimental groups used in the study. Table gives mean ± standard deviation 
or exact number. All prophylactic treatment listed is current treatment, and all acute treatment is used within 
one month before blood sampling. CH: cluster headache; F: females; M: males; RIN: RNA integrity value. aOther 
prophylactics used include lithium, frovatriptan, prednisolone, pizotifen, amitriptyline, mometasonfuroate and 
propranolol. bOther acute treatment used include morphine, naproxen, paracetamol, ibuprofen and rizatriptan. 
Medication is only included in the table when used by > 10% of cluster headache patients. cANOVA. dChi-
square test. eStudents t-test. fFisher exact test.
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profile did differ between participants with cluster headache and controls (P = 0.037). This indicates that differ-
ential expression even after correction for multiple testing might have been identified if a larger sample size had 
been used. More lenient P-value thresholds were used for the selection of genes for follow up analyses (Table 2). 
Similar results were obtained for episodic and chronic cluster headache when these subsets were tested against 
controls (Table 2). RT-qPCR analysis of four genes from the top 15 differentially expressed genes identified in 
the RNA-seq dataset could not fully confirm differential expression, with only two genes (LYRM9 and CCDC84) 
showing significantly differential expression (Fig. 1a). Irrespective of the statistical significance, we could replicate 
the fold-changes in expression (Fig. 1b).
Brain, oxidation and intracellular signalling functions associated with cluster headache. As 
interpreting individual genes is highly susceptible to false-positive findings, several analysis methods were applied 
to explore the RNA-seq dataset at the level of functional gene sets. First, a pathway enrichment analysis was per-
formed to identify functions overrepresented in lists of differentially expressed genes. Two P-value thresholds 
(P < 0.05 and P < 0.01; see Table 1 for the respective number of genes) for differential expression were used, 
and pathways that were overrepresented in both lists of genes were considered associated with cluster headache 
(Table 3). This way, the effect of possible false-positive associations was reduced. The top overrepresented pathway 
in genes with P < 0.05 is “GABA Receptor Signalling”. Most other overrepresented pathways involved signalling 
molecules, e.g. NUR77, CD28, Prolactin and IL-4.
Next, the Global Test was applied, which takes into account the full list of results, instead of merely a selection 
of differentially expressed genes. The Global Test is therefore especially suited to identify gene sets of which many 
genes show subtle associations while each individual gene association might be too small to be identified in the 
differential gene expression analysis27. Several functions associated with cluster headache are related to the brain, 
including “Calcium-release channel activity” (P = 0.0083), “Ganglioside metabolic process” (P = 0.0025) and 
Reactome pathways “GABA receptor activation” (P = 0.0066) and “Inhibition of voltage gated Ca2+channels via 
Gbeta/gamma subunits” (P = 0.0074) (Table 4). Other functions associated with cluster headache include several 
developmental and metabolism-related processes. Lastly, molecular function “Glutathione peroxidase activity” 
(P = 0.0013) and biological process “Response to hydroperoxide” (P = 0.006) are related to oxidation processes.
Association with previously identified differentially expressed genes and hypocretin. The 
Global Test was also applied to study the overlap with genes previously identified as differentially expressed 
in cluster headache24,25. To this end, the 9024 and 1,17225 previously identified genes were imported as custom 
gene sets into the Global Test. No association was found with cluster headache with either gene set in our data 
set (P = 0.33 and P = 0.14, respectively). To study the association with cluster headache with hypocretin in the 
P < 0.005 P < 0.01 P < 0.05 FDR < 0.05
CH vs 
controls 310 614 2,347 0
Episodic CH 
vs controls* 90 226 1,313 0
Chronic CH 
vs controls* 125 200 1,233 0
Table 2.  Number of differentially expressed genes based on different P-value thresholds. CH: cluster 
headache; FDR: false discovery rate. *Post-hoc analysis for cluster headache subtypes of differentially expressed 
genes for cluster headache.
Figure 1. RT-qPCR validation of genes differentially expressed between cluster headache patients and 
controls. Four genes were chosen from the top 15 differentially expressed genes between participants with 
cluster headache and controls. Data were normalized to TBP mRNA expression. (a) Gene expression measured 
by RT-qPCR in the cluster headache group relative to the expression in the control group. (b) Comparison of 
fold-change of gene expression in participants with cluster headache relative to controls measured by RNA-seq 
and RT-qPCR. Means ± SD, *P < 0.05; **P < 0.01.
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RNA-seq data, two custom gene sets were constructed in the STRING database and in the Euretos Knowledge 
Platform BRAIN. In STRING, 138 predicted functional partners of HCRT were identified, of which 49 were 
identified in blood with high enough expression. In BRAIN, 127 genes linked to HCRT were identified, of which 
66 were identified in blood with high enough expression. No association was found with cluster headache for the 
custom hypocretin gene sets in the RNA-seq data (P = 0.39 and P = 0.19, respectively).
Inflammation, mitochondria and intracellular signalling-related modules associated with 
cluster headache. Besides studying differentially expressed genes, weighted gene co-expression network 
analysis (WGCNA) was used to cluster genes in modules based on co-expression in the RNA-seq dataset, and 
to study the association of each of the modules with cluster headache. Because co-expression often results from 
genes being part of the same biological process, this method not only reduces the effect of multiple testing, but 
also greatly enhances the possibility for biological interpretation of an association. A total of 40 co-expression 
modules were identified, ranging in size from 34 to 2,903 genes, of which 6 showed an association with clus-
ter headache (Fig. 2). Three modules contained genes with higher expression in cluster headache (i.e. “Yellow”, 
“Grey60” and “Darkolivegreen” modules), as visualized in the bar graphs of the module eigengenes, which can be 
considered as the optimal summary of the expression pattern of the genes in the modules (Fig. 2). These modules 
are enriched for genes involved in metabolic pathways and intracellular signalling (Yellow), phagocytosis and 
brain-related signalling (Grey60) and mitochondria (Darkolivegreen). Lower expression in cluster headache was 
seen for the modules “Darkorange”, “Brown” and “Lightcyan”. These modules contain genes involved in inflam-
mation (Darkorange) and intracellular signalling (Brown and Lightcyan).
Discussion
In this study we determined whole blood gene expression profiles of 19 participants with episodic cluster head-
ache, 20 with chronic cluster headache, and 20 controls using an RNA-seq approach. To identify genes and path-
ways associated with cluster headache, analysis methods were applied that searched for association with single 
genes or for association with modules of co-expressed genes. Differential gene expression did not reveal a single 
cluster headache-associated gene that survived FDR multiple testing correction, hence differences in expression 
of genes in cluster headache, at best, are very modest.
As cluster headache-associated genes might be involved in multiple pathways, we conducted two types of 
functional enrichment analysis: functional enrichment in the lists of differentially expressed genes using a stand-
ard pathway enrichment method and the Global Test. These analyses suggest that inter- and intracellular sig-
nalling pathways involving brain-related molecules (e.g. GABA and ion channels) and inflammation-related 
molecules (e.g. CD28 and interleukin-4 (IL-4)), metabolism and oxidation might be involved in cluster headache. 
Although these findings should be interpreted with caution as inflammation-related processes seem to show up 
rather frequently in gene expression studies in blood28,29, inflammatory mediators such as IL-2 and soluble adhe-
sion molecules have repeatedly been associated with cluster headache11,12,30,31. Abnormal expression of inflamma-
tory genes in cluster headache was also observed in one of the earlier gene expression profiling studies25, although 
the genes identified in that study did not overlap with the genes found in our gene expression analysis.
Clustering analysis with WGCNA identified 40 modules of co-expressed genes in the gene expression data, 






P-value Count P-value Count
GABA Receptor Signaling 0.00053 13 0.043 4
Calcium-induced T 
Lymphocyte Apoptosis 0.0015 18 0.028 6
Nur77 Signaling in T 
Lymphocytes 0.0066 15 0.0040 7
CD28 Signaling in T 
Helper Cells 0.0098 28 0.021 10
Cdc42 Signaling 0.015 29 0.014 11
Role of BRCA1 in DNA 
Damage Response 0.017 21 0.023 8
IGF-1 Signaling 0.022 24 0.025 9
Actin Nucleation by ARP-
WASP Complex 0.023 15 0.0083 7
Prolactin Signaling 0.026 19 0.041 7
IL-4 Signaling 0.026 19 0.041 7
PTEN Signaling 0.043 25 0.045 9
Telomerase Signaling 0.044 23 0.026 9
Table 3.  Pathways significantly overrepresented in the genes differentially expressed in cluster headache. 
P-value thresholds for differential gene expression are P < 0.05 and P < 0.01. Pathways are included if 
overrepresented in lists of differentially expressed genes based on both P-value thresholds. DEGs: differentially 
expressed genes.
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provide potentially useful biological information with a disorder32, as gene co-expression modules capture a 
wide variety of biological factors, e.g. tissue composition and activity of transcription factors. Genes involved 
in inflammation and intracellular signalling were enriched in cluster headache-associated modules and the dif-
ferential gene expression analysis, supporting a pathophysiological role of these processes in cluster headache. 
Association with mitochondria was only found in the co-expression analysis. This finding, however, might still be 
relevant as altered mitochondrial function has been detected with phosphorus magnetic resonance spectroscopy 
in skeletal muscle and brain in cluster headache33,34 and migraine (reviewed by Sparaco et al.35).
A role for hypocretin in the pathophysiology of cluster headache has previously been suggested36–38. Global 
Test analysis of the custom hypocretin gene sets, however, failed to reveal evidence for involvement of hypocre-
tin in our RNA-seq data, which is in line with the absence of genetic association of HCRTR2 gene variants with 
cluster headache in the largest sample studied so far15. Blood may, however, not be the most appropriate tissue to 
study possible deregulation of the hypocretin pathway. Only 49/139 and 66/127 genes of the two custom hypocre-
tin gene sets could be measured reliably in blood. Moreover, changes in the hypocretin pathway may not be read-
ily reflected at the RNA level and the timing of blood sampling in relation to cluster headache attacks might be 
critical. A recent study in cerebrospinal fluid, in which significantly reduced hypocretin peptide levels were found 
in cluster headache patients39, further indicates that analysis of other tissues than blood is required to identify all 
genes and pathways involved in cluster headache. Then again, the worth of blood is supported by the finding that 
several biomarkers, including PACAP-3840 and methionine-enkephalin41, show altered levels during the course 
of a cluster headache attack in blood plasma.
Our results are in sharp contrast with an earlier gene profiling study in which microarray of immortalized 
lymphoblastoid cell lines identified over 1,100 differentially expressed genes, suggesting rather massive gene 
deregulation in cluster headache25. We are unsure how to explain these marked differences. Possible reasons 
might be the small sample size of only eight patients who were also using lithium, and the differences in stud-
ied tissue. Both tissue type and medication use have previously been shown to have substantial effect on gene 
expression42–44. The Global Test analysis in our study did not identify associations for this and another gene set 
previously found differentially expressed24,25. Moreover, when comparing our top differentially expressed genes 
(P < 0.005) we could confirm only two genes that were identified in both previous studies: mastermind like tran-
scriptional coactivator 2 (MAML2), a transcriptional coactivator involved in Notch signalling45, and lysozyme 
(LYZ), an antibacterial agent and possible inflammatory biomarker for Alzheimer disease46 and Niemann-Pick 
Type C47. Our results suggest that uncovering significant differentially expressed genes in cluster headache 
requires even larger study samples than the 59 we tested. Future studies on cluster headache and other episodic 
disorders should consider careful matching of study designs with previous studies, to enable result comparison 
Term ID Description P-value Count
Molecular Function
 GO:0004602 Glutathione peroxidase activity 0.0013 11
 GO:0015278 Calcium-release channel activity 0.0083 11
 GO:0043560 Insulin receptor substrate binding 0.0085 11
 GO:0031490 Chromatin DNA binding 0.0100 49
Biological process
 GO:0009235 Cobalamin metabolic process 0.0014 13
 GO:0001573 Ganglioside metabolic process 0.0025 16
 GO:0045682 Regulation of epidermis development 0.0026 30
 GO:0046033 AMP metabolic process 0.0037 13
 GO:0019082 Viral protein processing 0.0044 10
 GO:1901068 Guanosine-containing compound metabolic process 0.0047 24
 GO:0033194 Response to hydroperoxide 0.0060 14
 GO:0007220 Notch receptor processing 0.0061 18
 GO:0035357 Peroxisome proliferator activated receptor signaling pathway 0.0066 12
 GO:0008206 Bile acid metabolic process 0.0077 20
 GO:0032515 Negative regulation of phosphoprotein phosphatase activity 0.0083 13
 GO:0070987 Error-free translesion synthesis 0.0091 14
 GO:0045123 Cellular extravasation 0.0097 29
Reactome
 R-HSA-1660661 Sphingolipid de novo biosynthesis 0.0022 24
 R-HSA-428157 Sphingolipid metabolism 0.0043 48
 R-HSA-977444 GABA B receptor activation 0.0064 18
 R-HSA-977443 GABA receptor activation 0.0066 19
 R-HSA-997272 Inhibition of voltage gated Ca2+channels via Gbeta/gamma subunits 0.0074 11
 R-HSA-400042 Inhibition of insulin secretion by adrenaline noradrenaline 0.0075 16
 R-HSA-1296065 Inwardly rectifying K channels 0.0089 12
Table 4.  Differentially regulated functional gene sets identified with the Global Test.
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Figure 2. Gene co-expression modules in whole blood associated with cluster headache. Detection of 
co-expression modules in RNA-seq data of whole blood samples of cluster headache patients and controls 
using weighted gene co-expression network analysis (WGCNA). (a) The cluster dendrogram that gave rise to 
40 modules, indicated by different colours. (b–g) Bar graphs of the module eigengenes in controls, episodic 
(ECH) and chronic cluster headache (CCH) of the six modules associated with cluster headache. The module 
eigengene can be considered the optimal summary of the module-specific gene expression pattern. Top three 
pathways significantly overrepresented in each module are listed below each bar graph. P = P-value, C = count 
of genes in the module belonging to the pathway.
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and meta-analysis and should take into account the time of blood withdrawal relative to the occurrence of attacks 
(i.e. for cluster headache inside or outside an attack period).
In contrast to the previously published gene expression studies for cluster headache, we included episodic as 
well as chronic cluster headache patients and patients using various types of treatment (so the effect of a specific 
treatment on the differential gene expression analysis is low). Whereas including episodic and chronic cluster 
headache patients allowed stratification of patients by cluster headache subtype, given the fact that gene expres-
sion differences were only moderate and stratifying patients into subgroups would reduce power, most analy-
ses compared all cluster headache patients with controls. Although the majority of patients (25 out of 39) was 
included within one day from their last attack, also patients were included with a broader range in time during 
inclusion and last attack. No information was collected about the time between the inclusion and the start and 
end of the cluster period in the episodic patients, therefore the gene expression analyses could not be controlled 
for periodicity of the cluster headache attacks. Importantly, removing patients over 30 days from their last attack 
did not change the results of the differential gene expression analysis, reflecting the robustness of the results. By 
allowing a broader time range between inclusion and last attack, our results provide information not only on 
the gene expression profile related to having an attack per se, but also to having cluster headache and being in an 
attack cluster. On the other hand, the heterogeneity of the cohort may have suppressed effect sizes and the num-
ber of genes that reached the different P-value thresholds. Resampling the same patients during different stages 
of the disease or including patients only on the same day of a cluster headache attack may aid to unravel differ-
ential gene expression patterns directly caused by a cluster headache attack from those caused by other cluster 
headache-related pathways.
In summary, we performed the largest gene expression profiling study to date in whole blood samples of 
39 participants with cluster headache and 20 controls. Gene expression differences between cluster headache 
and controls were modest at the gene level. However, when analysed at the functional gene set level, genes 
associated with cluster headache were enriched for intracellular signalling cascades involving brain- and 
inflammation-related genes. Similar functions as well as mitochondrial functions were enriched in the cluster 
headache-associated modules of co-expressed genes. Larger study samples will be required to identify the full 
range of cluster headache-associated genes and pathways.
Methods
Participants. Male and female cluster headache patients and headache-free controls between 18 and 65 
years of age were recruited from our specialised headache out-patient clinic and as part of the Leiden University 
Cluster headache Analysis (LUCA) programme48. Diagnoses of episodic and chronic cluster headache were 
made according to ICHD-III criteria1. In a personal interview, information was collected on cluster headache his-
tory, medication use during the month before sampling, and active smoking and number of pack years (Table 1, 
Supplementary Table 3). Special effort was made to record the time of the last cluster headache attack prior to 
blood sampling. No inclusion criteria were formulated regarding time since last cluster headache attack, but as 
a result of including patients at an outpatient headache clinic most patients were in a “cluster period”. For each 
two participants with cluster headache one control was included that was matched for gender, age and smoking 
habits. Demographic features of the three experimental groups (controls, episodic cluster headache and chronic 
cluster headache) that were used for the RNA-seq analysis were compared using analysis of variance (ANOVA) 
for continuous variables and a chi-square test for categorical variables. Student’s t-test and Fisher’s exact test were 
used for comparisons between episodic and chronic cluster headache groups. All participants provided written 
informed consent and the study was approved by the medical ethics committee of the LUMC. All experiments 
were carried out in accordance with the relevant guidelines and regulations.
Peripheral venous blood samples were drawn at the LUMC between May 2014 and September 2015 into: 
1) EDTA-containing Vacutainer tubes for leukocyte differential count, and 2) PAXgene Blood RNA Tubes 
(PreAnalytiX, Qiagen, Hilden, Germany) for RNA isolation. Leukocyte counts were obtained using standard 
leukocyte differential count within two hours after blood collection. PAXgene Blood RNA Tubes were incubated 
overnight at room temperature and subsequently stored at − 20 °C.
RNA isolation and sequencing. PAXgene Blood RNA tubes were thawed and incubated for two hours at 
room temperature before RNA isolation using the PAXgene Blood miRNA kit (PreAnalytiX). Globin mRNA was 
depleted using the GLOBINclear™ Kit (Ambion, Austin, TX, USA). RNA quality was assessed using the Agilent 
2100 Bioanalyzer (Agilent, Foster City, CA, USA); all samples had a minimal RNA integrity number (RIN) of 7. 
RIN values of controls, episodic, and chronic cluster headache samples were 8.5 ± 0.3, 8.5 ± 0.3 and 8.3 ± 0.5, 
respectively (P-value controls vs episodic vs chronic cluster headache = 0.23, ANOVA). TruSeq RNA-Seq libraries 
were constructed with a circa 160 base pair (bp) insert size, followed by 90 bp paired-end RNA-sequencing on the 
Illumina Hiseq4000 by BGI Tech Solutions in Hong Kong (www.bgitechsolutions.com).
Sequencing data processing. RNA-seq reads were processed and aligned using the Gentrap pipeline 
(version 0.3.1) of the Sequencing Analysis Support Core (SASC) of the LUMC (https://humgenprojects.lumc.
nl/sasc/). In brief, adapter sequences were clipped from RNA-seq reads using Cutadapt (version 1.5)49 and 
low-quality bases were removed using Sickle (version 1.33)50. Next, sequencing reads were aligned to the human 
genome reference GRCh38 using TopHat (version 2.0.13)51, allowing only for unique alignments (max_mul-
tihits = 1, read-mismatches = 2, read-gap-length = 2 and mate-inner-dist = 160). Refseq transcript annotations 
were obtained from the UCSC Genome Browser (http://genome.ucsc.edu/index.html), and read fragments 
aligned to known exons were counted per gene using Htseq (version 0.6.1p1)52. All analyses were performed on 
the gene level.
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Quality of the RNA-seq dataset was assessed using FastQC53. Sample quality was assessed by: 1) hierarchical 
clustering of Spearman correlations between samples, 2) a multidimensional scaling (MDS) plot to visualize 
sample-to-sample distances, and 3) box plots of count distribution using R (version 3.2.2) and the Bioconductor 
package Limma (version 3.14.15)54. Next, the RNA-seq data was pre-processed for differential gene expression 
analysis. First, the data was filtered for low-expressed genes by removing genes with less than 1 CPM in at least 15 
samples. Differences in library sizes were then normalized using the trimmed mean of M-values (TMM) function 
in the Bioconductor EdgeR package (version 3.10.5)55. The data was converted to a logarithmic scale using the 
Limma voom transformation.
Differential gene expression analysis. Differential gene expression between cluster headache or the 
episodic or chronic subsets and control samples was calculated in Limma by fitting a linear model. To this end, 
data were normalized for age, gender, current smoking status, and leukocyte counts (basophils, eosinophils, lym-
phocytes, monocytes and neutrophils). Effects of medication use on differential gene expression were visualized 
in a heatmap of the top differentially expressed genes. Samples did not cluster on medication use, therefore, 
medication was not included as a cofactor in the differential gene expression analysis. FDR was used for multiple 
testing correction. In addition, several nominal P-value thresholds were applied to classify genes as differentially 
expressed for functional annotation (Table 2). The Global Test package was applied to test the overall gene expres-
sion data for differences between cluster headache and controls28.
Weighted gene co-expression network analysis. WGCNA was used to construct gene modules 
based on pairwise correlations between gene expression levels in the RNA-seq data56,57. First, outlier samples 
were removed more strictly than for the differential gene expression analysis, as they can have large impact on 
co-expression values. Seven additional samples were removed based on Spearman correlation analysis between 
samples and MDS plot inspection, leaving 18 control, 19 episodic and 15 chronic cluster headache samples. Next, 
a signed weighted adjacency matrix was calculated using the power of 15. The power of 15 was chosen from a 
range of 1 to 20, as it maximized the fit of the scale free topology (R2 > 0.8). Of the adjacency matrix, a topological 
overlap matrix-based dissimilarity measure was calculated that was used as input for hierarchical clustering. The 
dynamic tree-cutting algorithm was used to define the modules58. A total of 40 modules were identified, each 
with a minimal size of 30 genes. Pearson correlations between modules eigengenes (which can be considered 
the optimal summary of the module-specific gene expression pattern) and cluster headache were considered 
significant if P < 0.05.
Functional annotation of gene sets and modules. Enrichment analysis of canonical pathways in the 
lists of differentially expressed genes and the cluster headache-associated modules was performed using Ingenuity 
Pathways Analysis (IPA, Ingenuity Systems® ; http://www.ingenuity.com). Only experimentally observed links 
between genes and pathways were included. The full list of genes that remained after filtering of low-expressed 
genes (with less than 1 CPM in at least 15 samples) was used as reference gene set. Only pathways from which 
five or more genes were observed in a list of differentially expressed genes or in a module, or three or more in a 
module containing up to 100 genes, were included.
Next, the Global Test was applied to identify gene sets associated with cluster headache in the full list of 
genes27. The Global Test is especially designed to identify related genes consistently associated with a trait, but 
with small effects that may not reach significance when assessing individual genes. The Global Test might, there-
fore, identify more subtle functional associations with cluster headache than the gene set enrichment analysis 
in IPA. Gene sets were included if annotated by Gene Ontology (GO) terms or REACTOME pathways from the 
curated molecular signature database of the Broad institute (version 5.1) if they contained 10 or more genes. GO 
terms associated with cluster headache with P < 0.01 were summarized with REVIGO59 by removing redundant 
terms and only preserving GO terms with a maximum allowed similarity of 0.5.
Custom hypocretin gene sets were built manually in the STRING database for known and predicted protein 
associations (version 10, http://string-db.org/)60 and in the Euretos Knowledge Platform BRAIN (https://www.
euretos-brain.com/). In STRING, a manual gene set was built from predicted functional partners of HCRT based 
on gene co-expression, high-throughput experiments, databases and text mining; only predicted functional part-
ners with high confidence (confidence score of 0.9 or higher) were included. In BRAIN, all genes linked to the 
concepts “HCRT”, “HCRTC2” and “orexins” were included. These links are based on a wide variety of databases 
and text mining. Association of the custom hypocretin gene sets with cluster headache was calculated using the 
Global Test.
RT-qPCR validation. Findings from the RNA-sequencing data analysis were validated in the same RNA 
samples by real-time quantitative PCR (RT-qPCR). To this end, first-strand cDNA was synthesized with 
the RevertAid H Minus First Strand cDNA synthesis kit using random hexamer primers (Thermo Scientific 
Fermentas, Vilnius, Lithuania). RT-qPCR experiments were carried out in duplicate on the CFX384 Real-Time 
PCR Detection System (Bio-Rad, Hercules, CA, USA) using iQ™ SYBR® Green (Bio-Rad) as fluorophore and 
exon-spanning primers (Supplementary Table 2). TBP was selected as reference gene based on its low variabil-
ity in the RNA-seq data and high stability in RT-qPCR analysis. The RT-qPCR data was analysed with Bio-Rad 
CFX ManagerTM Software (version 3.1). Statistical analysis was performed using a linear model, correcting for 
age, gender, current smoking status and leukocyte counts (basophils, eosinophils, lymphocytes, monocytes and 
neutrophils).
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